{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:38:32Z","timestamp":1780450712189,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01BX005627"],"award-info":[{"award-number":["I01BX005627"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Diane Lindstrom Funds","award":["001"],"award-info":[{"award-number":["001"]}]},{"name":"Wisconsin Ovarian Cancer Alliance","award":["001"],"award-info":[{"award-number":["001"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA238423"],"award-info":[{"award-number":["1R01CA238423"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01GM135631"],"award-info":[{"award-number":["R01GM135631"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cheminform"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Focused screening on target-prioritized compound sets can be an efficient alternative to high throughput screening (HTS). For most biomolecular targets, compound prioritization models depend on prior screening data or a target structure. For phenotypic or multi-protein pathway targets, it may not be clear which public assay records provide relevant data. The question also arises as to whether data collected from disparate assays might be usefully consolidated. Here, we report on the development and application of a data mining pipeline to examine these issues. To illustrate, we focus on identifying inhibitors of oxidative phosphorylation, a druggable metabolic process in epithelial ovarian tumors. The pipeline compiled 8415 available OXPHOS-related bioassays in the PubChem data repository involving 312,093 unique compound records. Application of PubChem assay activity annotations, PAINS (Pan Assay Interference Compounds), and Lipinski-like bioavailability filters yields 1852 putative OXPHOS-active compounds that fall into 464 clusters. These chemotypes are diverse but have relatively high hydrophobicity and molecular weight but lower complexity and drug-likeness. These chemotypes show a high abundance of bicyclic ring systems and oxygen containing functional groups including ketones, allylic oxides (alpha\/beta unsaturated carbonyls), hydroxyl groups, and ethers. In contrast, amide and primary amine functional groups have a notably lower than random prevalence. UMAP representation of the chemical space shows strong divergence in the regions occupied by OXPHOS-inactive and -active compounds. Of the six compounds selected for biological testing, 4 showed statistically significant inhibition of electron transport in bioenergetics assays. Two of these four compounds, lacidipine and esbiothrin, increased in intracellular oxygen radicals (a major hallmark of most OXPHOS inhibitors) and decreased the viability of two ovarian cancer cell lines, ID8 and OVCAR5. Finally, data from the pipeline were used to train random forest and support vector classifiers that effectively prioritized OXPHOS inhibitory compounds within a held-out test set (ROCAUC 0.962 and 0.927, respectively) and on another set containing 44 documented OXPHOS inhibitors outside of the training set (ROCAUC 0.900 and 0.823). This prototype pipeline is extensible and could be adapted for focus screening on other phenotypic targets for which sufficient public data are available.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Scientific contribution<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Here, we describe and apply an assay data mining pipeline to compile, process, filter, and mine public bioassay data. We believe the procedure may be more broadly applied to guide compound selection in early-stage hit finding on novel multi-protein mechanistic or phenotypic targets. To demonstrate the utility of our approach, we apply a data mining strategy on a large set of public assay data to find drug-like molecules that inhibit oxidative phosphorylation (OXPHOS) as candidates for ovarian cancer therapies.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s13321-024-00906-0","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T17:01:46Z","timestamp":1728320506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Data mining of PubChem bioassay records reveals diverse OXPHOS inhibitory chemotypes as potential therapeutic agents against ovarian cancer"],"prefix":"10.1186","volume":"16","author":[{"given":"Sejal","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicha","family":"Boonpattrawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvinder","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Barroilhet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish S.","family":"Patankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer S.","family":"Ericksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"906_CR1","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.semcancer.2021.07.012","volume":"86","author":"GP Pinto","year":"2022","unstructured":"Pinto GP, Hendrikse NM, Stourac J, Damborsky J, Bednar D (2022) Virtual screening of potential anticancer drugs based on microbial products. Semin Cancer Biol 86:1207\u20131217","journal-title":"Semin Cancer Biol"},{"key":"906_CR2","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2174\/1568026619666190816101948","volume":"19","author":"SFL da Silva Rocha","year":"2019","unstructured":"da Silva Rocha SFL, Olanda CG, Fokoue HH, Sant\u2019Anna CMR (2019) Virtual screening techniques in drug discovery: review and recent applications. Curr Top Med Chem 19:1751\u20131767","journal-title":"Curr Top Med Chem"},{"key":"906_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.104851","volume":"137","author":"B Shaker","year":"2021","unstructured":"Shaker B, Ahmad S, Lee J, Jung C, Na D (2021) In silico methods and tools for drug discovery. Comput Biol Med 137:104851","journal-title":"Comput Biol Med"},{"key":"906_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1124\/pharmrev.120.000246","volume":"73","author":"F Ballante","year":"2021","unstructured":"Ballante F, Kooistra AJ, Kampen S, de Graaf C, Carlsson J (2021) Structure-based virtual screening for ligands of G protein-coupled receptors: what can molecular docking do for you? Pharmacol Rev 73:527\u2013565","journal-title":"Pharmacol Rev"},{"key":"906_CR5","doi-asserted-by":"publisher","first-page":"i103","DOI":"10.1093\/bioinformatics\/btad234","volume":"39","author":"A Dalk\u0131ran","year":"2023","unstructured":"Dalk\u0131ran A, Atakan A, Rifaio\u011flu AS et al (2023) Transfer learning for drug-target interaction prediction. Bioinformatics 39:i103\u2013i110","journal-title":"Bioinformatics"},{"key":"906_CR6","doi-asserted-by":"publisher","first-page":"8683","DOI":"10.1021\/acs.jmedchem.9b02147","volume":"63","author":"C Cai","year":"2020","unstructured":"Cai C, Wang S, Xu Y et al (2020) Transfer learning for drug discovery. J Med Chem 63:8683\u20138694","journal-title":"J Med Chem"},{"key":"906_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/bdcc4030016","volume":"4","author":"M Salem","year":"2020","unstructured":"Salem M, Khormali A, Arshadi AK, Webb J, Yuan J-S (2020) TranScreen: transfer learning on graph-based anti-cancer virtual screening model. Big Data Cogn Comput 4:16","journal-title":"Big Data Cogn Comput"},{"key":"906_CR8","doi-asserted-by":"publisher","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","volume":"51","author":"S Kim","year":"2022","unstructured":"Kim S, Chen J, Cheng T et al (2022) PubChem 2023 update. Nucleic Acids Res 51:D1373\u2013D1380","journal-title":"Nucleic Acids Res"},{"key":"906_CR9","doi-asserted-by":"publisher","first-page":"D930","DOI":"10.1093\/nar\/gky1075","volume":"47","author":"D Mendez","year":"2019","unstructured":"Mendez D, Gaulton A, Bento AP et al (2019) ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res 47:D930-d940","journal-title":"Nucleic Acids Res"},{"key":"906_CR10","doi-asserted-by":"publisher","first-page":"D1045","DOI":"10.1093\/nar\/gkv1072","volume":"44","author":"MK Gilson","year":"2015","unstructured":"Gilson MK, Liu T, Baitaluk M, Nicola G, Hwang L, Chong J (2015) BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology. Nucleic Acids Res 44:D1045\u2013D1053","journal-title":"Nucleic Acids Res"},{"key":"906_CR11","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3390\/cancers14092297","volume":"14","author":"A Kapur","year":"2022","unstructured":"Kapur A, Mehta P, Simmons AD et al (2022) Atovaquone: an inhibitor of oxidative phosphorylation as studied in gynecologic cancers. Cancers (Basel) 14:2297","journal-title":"Cancers (Basel)"},{"key":"906_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3390\/cancers10090337","volume":"10","author":"AP Nayak","year":"2018","unstructured":"Nayak AP, Kapur A, Barroilhet L, Patankar MS (2018) Oxidative phosphorylation: a target for novel therapeutic strategies against ovarian cancer. Cancers (Basel) 10:337","journal-title":"Cancers (Basel)"},{"key":"906_CR13","doi-asserted-by":"publisher","first-page":"14276","DOI":"10.1021\/acs.jmedchem.0c01013","volume":"63","author":"Y Xu","year":"2020","unstructured":"Xu Y, Xue D, Bankhead A III, Neamati N (2020) Why all the fuss about oxidative phosphorylation (OXPHOS)? J Med Chem 63:14276\u201314307","journal-title":"J Med Chem"},{"key":"906_CR14","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.3390\/ijms20133316","volume":"20","author":"ME Garc\u00eda Rubi\u00f1o","year":"2019","unstructured":"Garc\u00eda Rubi\u00f1o ME, Carrillo E, Ruiz Alcal\u00e1 G, Dom\u00ednguez-Mart\u00edn A, Marchal JA, Boulaiz H (2019) Phenformin as an anticancer agent: challenges and prospects. Int J Mol Sci 20:3316","journal-title":"Int J Mol Sci"},{"key":"906_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, Daver N, Mahendra M et al (2023) Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29:115\u2013126","journal-title":"Nat Med"},{"key":"906_CR16","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41416-023-02394-9","volume":"129","author":"ND Machado","year":"2023","unstructured":"Machado ND, Heather LC, Harris AL, Higgins GS (2023) Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities. Br J Cancer 129:897\u2013899","journal-title":"Br J Cancer"},{"key":"906_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1530\/REP-22-0265","volume":"165","author":"A Kapur","year":"2023","unstructured":"Kapur A, Ayuso JM, Rehman S et al (2023) Oxidative phosphorylation inhibitors inhibit proliferation of endometriosis cells. Reproduction 165:617\u2013628","journal-title":"Reproduction"},{"key":"906_CR18","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41598-018-19261-w","volume":"8","author":"A Kapur","year":"2018","unstructured":"Kapur A, Beres T, Rathi K et al (2018) Oxidative stress via inhibition of the mitochondrial electron transport and Nrf-2-mediated anti-oxidative response regulate the cytotoxic activity of plumbagin. Sci Rep 8:1073","journal-title":"Sci Rep"},{"key":"906_CR19","doi-asserted-by":"publisher","first-page":"27530","DOI":"10.1038\/srep27530","volume":"6","author":"A Kapur","year":"2016","unstructured":"Kapur A, Felder M, Fass L et al (2016) Modulation of oxidative stress and subsequent induction of apoptosis and endoplasmic reticulum stress allows citral to decrease cancer cell proliferation. Sci Rep 6:27530","journal-title":"Sci Rep"},{"key":"906_CR20","first-page":"2548","volume":"32","author":"S Zeng","year":"2015","unstructured":"Zeng S, Kapur A, Patankar MS, Xiong MP (2015) Formulation, characterization, and antitumor properties of trans- and cis-citral in the 4T1 breast cancer xenograft mouse model. Pharm Res 32:2548\u20132558","journal-title":"Pharm Res"},{"key":"906_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053178","volume":"7","author":"Y Liu","year":"2012","unstructured":"Liu Y, Whelan RJ, Pattnaik BR et al (2012) Terpenoids from Zingiber officinale (Ginger) induce apoptosis in endometrial cancer cells through the activation of p53. PLoS ONE 7:e53178","journal-title":"PLoS ONE"},{"key":"906_CR22","doi-asserted-by":"publisher","first-page":"W623","DOI":"10.1093\/nar\/gkp456","volume":"37","author":"Y Wang","year":"2009","unstructured":"Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, Bryant SH (2009) PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res 37:W623-633","journal-title":"Nucleic Acids Res"},{"key":"906_CR23","doi-asserted-by":"publisher","first-page":"11471","DOI":"10.1038\/s41598-019-47261-x","volume":"9","author":"Y Alharbi","year":"2019","unstructured":"Alharbi Y, Kapur A, Felder M et al (2019) Plumbagin-induced oxidative stress leads to inhibition of Na(+)\/K(+)-ATPase (NKA) in canine cancer cells. Sci Rep 9:11471","journal-title":"Sci Rep"},{"key":"906_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman L (2001) Random forests. Mach Learn 45:5\u201332","journal-title":"Mach Learn"},{"key":"906_CR25","unstructured":"Permutation Importance vs Random Forest Feature Importance (MDI). https:\/\/scikit-learn.org\/stable\/auto_examples\/inspection\/plot_permutation_importance.html."},{"key":"906_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S0021-9258(19)84014-0","volume":"238","author":"B Chance","year":"1963","unstructured":"Chance B, Hollunger G (1963) Inhibition of electron and energy transfer in mitochondria: I. Effects of amytal, thiopental, rotenone, progesterone, and methylene glycol. J Biol Chem 238:418\u2013431","journal-title":"J Biol Chem"},{"key":"906_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.celrep.2018.03.032","volume":"23","author":"A Naguib","year":"2018","unstructured":"Naguib A, Mathew G, Reczek CR et al (2018) Mitochondrial complex I inhibitors expose a vulnerability for selective killing of Pten-null cells. Cell Rep 23:58\u201367","journal-title":"Cell Rep"},{"key":"906_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1124\/jpet.104.068312","volume":"311","author":"B Brunmair","year":"2004","unstructured":"Brunmair B, Lest A, Staniek K et al (2004) Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I. J Pharmacol Exp Ther 311:109\u2013114","journal-title":"J Pharmacol Exp Ther"},{"key":"906_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1073\/pnas.0237315100","volume":"100","author":"H Miyadera","year":"2003","unstructured":"Miyadera H, Shiomi K, Ui H et al (2003) Atpenins, potent and specific inhibitors of mitochondrial complex II (succinate-ubiquinone oxidoreductase). Proc Natl Acad Sci 100:473\u2013477","journal-title":"Proc Natl Acad Sci"},{"key":"906_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/minf.202000005","volume":"39","author":"J Hemmerich","year":"2020","unstructured":"Hemmerich J, Troger F, F\u00fczi B, Ecker GF (2020) Using machine learning methods and structural alerts for prediction of mitochondrial toxicity. Mol Inform 39:e2000005","journal-title":"Mol Inform"},{"key":"906_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-1-61779-108-6_12","volume":"740","author":"TL Riss","year":"2011","unstructured":"Riss TL, Moravec RA, Niles AL (2011) Cytotoxicity testing: measuring viable cells, dead cells, and detecting mechanism of cell death. Methods Mol Biol 740:103\u2013114","journal-title":"Methods Mol Biol"},{"key":"906_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1021\/ci700286x","volume":"48","author":"P Ertl","year":"2008","unstructured":"Ertl P, Roggo S, Schuffenhauer A (2008) Natural product-likeness score and its application for prioritization of compound libraries. J Chem Inf Model 48:68\u201374","journal-title":"J Chem Inf Model"},{"key":"906_CR33","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1021\/acs.jmedchem.5b00294","volume":"58","author":"DA Erlanson","year":"2015","unstructured":"Erlanson DA (2015) Learning from PAINful lessons. J Med Chem 58:2088\u20132090","journal-title":"J Med Chem"},{"key":"906_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1021\/acschembio.7b00903","volume":"13","author":"JB Baell","year":"2018","unstructured":"Baell JB, Nissink JWM (2018) Seven Year itch: pan-assay interference compounds (PAINS) in 2017-utility and limitations. ACS Chem Biol 13:36\u201344","journal-title":"ACS Chem Biol"},{"key":"906_CR35","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1021\/ci100050t","volume":"50","author":"D Rogers","year":"2010","unstructured":"Rogers D, Hahn M (2010) Extended-connectivity fingerprints. J Chem Inf Model 50:742\u2013754","journal-title":"J Chem Inf Model"},{"key":"906_CR36","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3109\/17482968.2011.572978","volume":"12","author":"JE Huggins","year":"2011","unstructured":"Huggins JE, Wren PA, Gruis KL (2011) What would brain-computer interface users want? Opinions and priorities of potential users with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 12:318\u2013324","journal-title":"Amyotroph Lateral Scler"},{"key":"906_CR37","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1021\/acs.jcim.3c00912","volume":"63","author":"M Alnammi","year":"2023","unstructured":"Alnammi M, Liu S, Ericksen SS et al (2023) Evaluating scalable supervised learning for synthesize-on-demand chemical libraries. J Chem Inf Model 63:5513\u20135528","journal-title":"J Chem Inf Model"},{"key":"906_CR38","doi-asserted-by":"crossref","unstructured":"McInnes L, Healy J. UMAP: uniform manifold approximation and projection for dimension reduction. ArXiv. 2018; http:\/\/arxiv.org\/abs\/1802.03426.","DOI":"10.21105\/joss.00861"}],"container-title":["Journal of Cheminformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13321-024-00906-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13321-024-00906-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13321-024-00906-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T05:05:15Z","timestamp":1728363915000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcheminf.biomedcentral.com\/articles\/10.1186\/s13321-024-00906-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1186\/s13321-024-00906-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4325663\/v1","asserted-by":"object"}]},"ISSN":["1758-2946"],"issn-type":[{"value":"1758-2946","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]},"assertion":[{"value":"25 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as human subjects and vertebrate animals were not included in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}